Edesa Biotech Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. The topical therapy employs a novel mechanism of action, and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in contact dermatitis patients. We are currently enrolling subjects in a Phase 2b clinical study evaluating EB01.
We also hold exclusive rights to two late-stage monoclonal antibodies, designated as EB05 and EB06, which block certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including the inflammation associated with infectious diseases. Due to the global health emergency, we have prioritized the development of EB05 as a potential treatments for acute respiratory distress syndrome (ARDS) in hospitalized COVID-19 patients.
Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada
Fasken Martineau DuMoulin LLP
Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1
Tel: (800) 564-6253